Daiichi Sankyo Company, Limited and Eli Lilly and Company today announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application for prasugrel to the USFDA. Prasugrel is an oral antiplatelet agent, initially in development for the treatment of patients with acute coronary syndrome who are managed with percutaneous coronary intervention (PCI), including coronary stenting.
If approved for marketing in the United States, the trade name for prasugrel will be Effient company officials added."We are elated," said J. Anthony Ware, M.D., Lilly vice president and cardiovascular/acute care platform leader for prasugrel. "We feel confident in the strength and completion of this submission package, and plan to complete our submission in Europe in the first quarter of 2008. The benefit/risk profile of this compound, in comparison with the current standard of care, has the potential to improve outcomes for ACS patients undergoing PCI."
No comments:
Post a Comment